The use of pycnogenol in the treatment of melasma

Scharf, Camila; Delfes, Manuela Ferrasso Zuchi; Reis, Larissa Montanheiro dos; Garbers, Luiz Eduardo Fabrício de Melo; Passos, Paola C. Vieira da Rosa; Torre, Deborah Skusa de

doi:10.5935/scd1984-8773.201573663

Cited by 7 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study had a 42% dropout rate (for unexplained reasons); however, some improvement was reported in 94% of participants, and there was a reduction of 58% in the mMASI scores and 19% in the MELASQoL scores. Most of the participants had fair skin (phototypes II and III) 11 …”

Section: Discussionmentioning

confidence: 99%

“…Ex vivo studies have demonstrated that the antioxidant properties of pycnogenol are superior to those of vitamin E and C; 8,9 it can reduce the melanin density in skin fragments exposed to UVA, UVB, infrared radiation and visible light 10 . Several non‐controlled studies have demonstrated the depigmenting effects of pycnogenol in melasma 11–14 …”

Section: Introductionmentioning

confidence: 99%

“…10 Several noncontrolled studies have demonstrated the depigmenting effects of pycnogenol in melasma. [11][12][13][14] In addition to oxidative damage in the upper dermis, melasma shows a greater expression of dermal CD34, which is related to an increase in the number and size of blood vessels. 15,16 Angiogenesis in melasma manifests clinically as erythema and telangiectasias.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double‐blind, randomized, placebo‐controlled trial

Lima

Dias

Espósito

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Melasma can be recalcitrant to treatment, and relapses are common. Pycnogenol has been reported to be effective in treating melasma. Objective To compare the efficacy, safety and tolerability of 75 mg pycnogenol taken orally twice a day vs. a placebo, in association with the triple combination and broad‐spectrum sunscreen for the treatment of facial melasma. Methods A randomized, double‐blind, parallel, placebo‐controlled study was conducted on 44 women with facial melasma in a single centre from May 2019 through November 2019. Patients with melasma were randomly assigned to orally take 75 mg pycnogenol (PYC) or a placebo (PLAC) twice a day for 60 days. Both groups also received tinted sunscreen [Sun Protection Factor (SPF) 50; Persistent Pigment Darkening (PPD) 17] for daytime use and a topical triple combination at bedtime. The primary outcome was a change from the baseline Modified Melasma Area Severity Index (mMASI) score. Secondary outcomes were improvements in the patients' quality of life (MELASQoL), colorimetric indices and Global Aesthetic Improvement Scale (GAIS). Results All participants completed the trial. The mean (SD) age of the participants was 39 (7) years, and 91% were phototypes III–IV. Both groups exhibited a reduction in mMASI scores, MELASQoL scores and colour contrast (P < 0.01). The mean (CI 95%) reductions of the mMASI scores were 49% (36–61%) for PYC and 34% (16–47%) for PLAC. The reductions in mMASI scores and colorimetric contrast were superior for the PYC group (P < 0.05). The analysis of GAIS resulted in an improvement of 86% (CI 95%: 68–96%) for the participants in the PYC group and 55% (CI 95%: 32–73%) for those in the PLAC group. There were no adverse effects related to oral treatment. Conclusion Pycnogenol is well‐tolerated and increases the effectiveness of broad‐spectrum sunscreen and the triple combination in the treatment of facial melasma in women.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double‐blind, randomized, placebo‐controlled trial

Lima

Dias

Espósito

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Oral pycnogenol 50 mg twice daily has been suggested to treat melasma, reducing 58% of MASI in 31 Brazilian women after 90 days [ 87 ]. Another case series enrolled 30 Chinese women with melasma, who took 25 mg pycnogenol three times daily for 30 days, leading to a 32% mean area reduction and a 22% intensity reduction of facial melasma [ 86 ].…”

Section: Introductionmentioning

confidence: 99%

Update on Melasma—Part II: Treatment

Cassiano

Espósito²,

Silva³

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Melasma is a prevalent chronic relapsing pigmentary disorder that affects photoexposed areas, especially in women of childbearing age. Although there is currently no curative treatment available for melasma, this manuscript critically reviews the knowledge regarding photoprotection, topical and oral therapies, and procedures such as peelings, laser, and microneedling that represent the main strategies for control and prevention of this disease. As the pathogenesis of melasma is not entirely understood, there are prospects for the development of new therapeutic strategies that might act on the pathways that promote sustained pigmentation rather than merely decreasing melanin synthesis and removing melanin from the epidermis.

show abstract

“…[3,4] Phenolic derivative from aerial parts of the plant showed presence of pycnogenol. [5] The compound Pycnogenol was reported and the studies also showed its role in oxidative stress in several cell systems by doubling the intracellular synthesis of antioxidative enzymes and by acting as a potent scavenger of free radicals. [2] In this present study, attempt is made in the further screening of phytoconstituents which are of biological importance.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Rajeswari¹

2020

IJGP

View full text Add to dashboard Cite

Objective:The aim of the present study is to screen for the phytochemical constituents present in the ethanolic extract of whole plant of Pinus maritimus (PM). Method: The ethanolic extract of the dried whole plant of PM is subjected to preliminary phytochemical screening which showed the presence of major phytoconstituents such as phenols, flavonoids, and alkaloids. The extract was screened for its antioxidant activity by 2,2'-diphenyl-1-picrylhydrazyl, hydroxyl radical, ferric reducing antioxidant potential, and nitric oxide scavenging assay. Further, the ethanolic extract was subjected to fingerprinting technique high-pressure thin-layer chromatography. Reverse-phase highperformance liquid chromatography (HPLC) was performed to estimate the amount of total phenolics, flavonoids, and alkaloids quantitatively in isocratic mode. Results: Phytochemical screening of the ethanolic extract of the plant showed the presence of important active constituents such as alkaloids, flavonoids, phenolics, and terpenoids. The study also revealed the potential antioxidant activity of the extract with IC 50 value. Reverse-phase HPLC showed 0.119 μg/ml of total phenolics, 0.257 μg/ml of alkaloids, and 0.0016 μg /ml of flavonoids. Conclusion: Scientific evaluation of this plant was carried out which is very important for the standardization of the plant-based drug. PM is one which has therapeutic importance as it showed important phytoconstituents.

show abstract

The use of pycnogenol in the treatment of melasma

Cited by 7 publications

References 9 publications

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double‐blind, randomized, placebo‐controlled trial

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double‐blind, randomized, placebo‐controlled trial

Update on Melasma—Part II: Treatment

Untitled

Contact Info

Product

Resources

About